PA
REGN icon

Procyon Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Procyon Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Sell
607
-282
-32% -$192K 0.02% 408
2026
Q1 		$687K Buy
889
+449
+102% +$344K 0.03% 315
2025
Q4 		$340K Sell
440
-23
-5% -$15.6K 0.02% 410
2025
Q3 		$260K Sell
463
-68
-13% -$38.4K 0.02% 427
2025
Q2 		$279K Sell
531
-5,942
-92% -$3.32M 0.03% 385
2025
Q1 		$4.11M Buy
6,473
+2,992
+86% +$2.06M 0.25% 90
2024
Q4 		$2.48M Sell
3,481
-544
-14% -$457K 0.16% 136
2024
Q3 		$4.23M Buy
4,025
+244
+6% +$272K 0.29% 82
2024
Q2 		$3.97M Buy
3,781
+308
+9% +$299K 0.29% 77
2024
Q1 		$3.34M Buy
3,473
+268
+8% +$255K 0.26% 91
2023
Q4 		$2.81M Buy
3,205
+174
+6% +$143K 0.24% 101
2023
Q3 		$2.49M Buy
3,031
+1,823
+151% +$1.43M 0.26% 96
2023
Q2 		$868K Buy
+1,208
New +$931K 0.11% 174
2020
Q3 		– Sell
-45
Closed -$28K – 848
2020
Q2 		$28K Hold
45
– – 0.01% 484
2020
Q1 		$22K Hold
45
– – 0.01% 469
2019
Q4 		$17K Buy
+45
New +$15.1K 0.01% 528

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Procyon Advisors's REGN Position: Q2 2026 in Review

Procyon Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, selling an estimated $192K and leaving 607 shares worth $378K. The position accounts for 0.02% of the portfolio, ranked #408.

Procyon Advisors first reported a position in REGN in Q4 2019 and has held it in 16 quarters since. The position peaked at $4.23M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Procyon Advisors held 607 shares of Regeneron Pharmaceuticals worth $378K as of Q2 2026.
  • Procyon Advisors sold 282 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $192K.
  • Regeneron Pharmaceuticals made up 0.02% of Procyon Advisors's portfolio in Q2 2026, its #408 holding.
  • Procyon Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
  • Procyon Advisors's Regeneron Pharmaceuticals position peaked at $4.23M in Q3 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.